Fevzi Yalniz - University of Kentucky

Education/Academic qualification

Post Doctoral Fellow, University Of Texas School of Allied Health Sciences

2019

Residency, Yeditepe University, Istanbul, Turkey

2011

Doctor of Medicine, Hacettepe University

2004

5 Active

24-HEM-21-DP (DCC-3014-02-001): A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
Yalniz, F. (PI)
Deciphera Pharmaceuticals LLC
4/24/25 → 4/24/27
Project: Research project
24-NHL-36-CB-PMC: An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy (Long term follow-up to NHL 31)
Yalniz, F. (PI)
Caribou Biosciences Incorporated
6/3/24 → 6/3/26
Project: Research project
23-LEUK-23-CC: ACE-536-MF-002, A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy
Yalniz, F. (PI)
Celgene
11/27/23 → 11/27/25
Project: Research project
23-NHL-31-CB-PMC: CB-10A, A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Yalniz, F. (PI)
Caribou Biosciences Incorporated
9/8/23 → 9/8/25
Project: Research project
University of Kentucky Center for Cancer Metabolism (Admin Core)
Zhou, B. (PI), Brainson, C. (CoI), Chaiswing, L. (CoI), D'Orazio, J. (CoI), Duncan, E. (CoI), Fan, W.-M. (CoI), Fong, K. W. (CoI), Hao, Z. (CoI), Higashi, R. (CoI), Jia, J. (CoI), Lane, A. (CoI), Liu, J. (CoI), Liu, X. (CoI), Moseley, H. (CoI), Myint, Z. (CoI), Rellinger, E. (CoI), Thorson, J. (CoI), Van Eldik, L. (CoI), Vanderford, N. (CoI), Wang, C. (CoI), Weiss, H. (CoI) & Yalniz, F. (CoI)
National Institute of General Medical Sciences
3/1/17 → 12/31/26
Project: Research project